# Clinical Efficacy and Optimal Concentration of Ketotifen Ophthalmic on Allergic Conjunctivitis and Vernal Conjunctivitis

Yoshifumi Fujita\*, Yasuyo Inomoto, Yasuo Mimura Department of Ophthalmology, Tokushima University

Satoru Miki
Department of Ophthalmology, Tosa Shimin Hospital

Tomoko Iwase Department of Ophthalmology, Kyosai Kumiai Shikoku Central Hospital

Toshihiko Kato
Department of Ophthalmology, Koseiren Awa Hospital

Ketotifen ophthalmic (0.05% or 0.025%) was administered to 29 patients with allergic conjunctivitis, and its elinical effectiveness and optimal concentration were evaluated. With respect to global improvement, the improvement rate for the 0.05% preparation was higher than that for to 0.025% preparation: the former was 85% and the latter was 23%. No side effects and no abnormal laboratory findings were noted. The utility of the 0.05% preparation was thus higher than that of the 0.025% preparation (p< 0.01). These results confirm that 0.05% ketotifen ophthalmic is superior to 0.025% ketotifen ophthalmic.

Key words: Ketotifen ophthalmic; Allergic conjunctivitis; Vernel conjunctivitis, 0.05% vs 0.025% preparation

# Introduction

Ketotifen ophthalmic solution (HC ophthalmic solution) is an ophthalmic solution that has ketotifen (Figure 1) as the main ingredient. Ketotifen is expected to have a therapeutic effect in allergic conjunctivitis and verual conjunctivitis if applied in the field of ophthalmology, because it has antiallergy action and antihistamine action [1-5].

As for the safety of HC ophthalmic solution, no particularly noteworthy effects on the outer ocular regions, anterior eye segment, or other ocular tissues were reported in concentrations up to 0.8% in a 13-week repeated instillation test using rabbits [6].

The safety of 0.05% and 0.1% HC ophthalmic solution was studed in a phase I trial in healthy adults [7]. As a result, 0.1% solution was judged to be undesirable in practice because there were many more complaints of transient "stinging" by 0.1% solution than by 0.05% solution. 0.05% solution was consequently selected as the clinical concentration.

As for the efficacy of HC ophthalmic solution, excellent results were reported by multicenter cooperative research on 0.05% HC ophthalmic solution in allergic conjunctivitis and vernal conjunctivitis [8]. On the other hand, the efficacy of HC ophthalmic solutions of concentrations lower than 0.05% has not been studied. The efficacy and safety of 0.05% and 0.025% HC ophthalmic solutions were therefore compared at Tokushima University and associated institutions and the results reported here.

Figure 1. Chemical structure of ketotifen.

# I. Subjects and Trial Method

#### 1. Subjects

Subjects among patients examined by the four institutions shown in Table 1 between August 1987 and April 1988 diagnosed with vernal conjunctivitis or allergic conjunctivitis in whom the participation of type I allergy had been confirmed by the cosinophil count in conjunctival scrapings, RAST IgE antibodies, and skin reactions served as the subjects. However, patients with other eye diseases (such as glaucoma, infectious conjunctivitis, and trachoma), contact lens wearers, patients who had undergone desensitization or modulation therapy within the last six months, pregnant women, nursing mothers, and women who might be pregnant, children less than 5 years of age, and subjects deemed inappropriate for incorporation in this trial by the attending physician were excluded as subjects.

Furthermore, administration of the ophthalmic solutions was begun after obtaining oral or written consent subsequent to an explanation of the nature of the trial, etc. to the patient or his or her family prior to beginning the trial.

Tokushima University	Department of Ophthalmology	Y. Nimura, Y. Fujita, Y. Inomoto
Tosa Shimin Hospital	Department of Ophthalmology	S. Miki
Kyosai Kumiai Shikoku Central Hospital	Department of Ophthalmology	T. Iwase
Koseiren Awa Hospital	Department of Ophthalmology	T. Kato

Table 1. Participating institutions.

# 2. Trial drugs and allocation

0.05% HC ophthalmic solution (0.05% solution): colorless, transparent aqueous solution containing 0.5 mg of ketotifen per milliliter.

0.025% HC ophthalmic solution (0.025% solution): colorless, transparent aqueous solution containing 0.25 mg of ketotifen per milliliter.

As a general rule, the trial drugs (0.05% and 0.025% solutions) were allocated in alternation in the order in which the patients visited the hospital.

# 3. Administration method and duration

Following a from 3-day to 1-week preadministration observation period, the prescribed tests were conducted and the subject patients selected. The duration of treatment as a general rule was set at 4 weeks during which time the HC ophthalmic solution was instilled one or two drops at a time four times a day (morning, afternoon, evening, and before bed). When the condition was cured in less than 4 weeks, that point in time was taken as the end of the trial and the prescribed studies and evaluations conducted.

#### 4. Discontinuation of administration

The attending physician had the prerogative to discontinue instillation when grave side effects appeared; when abnormal clinical test values were discovered, or when the clinical symptoms and findings exacerbated. However, the prescribed studies and evaluations were to be conducted at the time of discontinuation when the trial was discontinued and the reasons for discontinuation and findings at the time of discontinuation, etc. were to be recorded on the case chart.

# 5. Concomitant drugs

All oral and ophthalmic drugs that might affect the evaluation of the efficacy of the trial drug such as antihistamines and antiallergy drugs other than the trial drug were prohibited during the trial. Use of steroids (oral and ophthalmic) from the preadministration observation period was allowed to continue only when their use was judged to be unavoidable given the severity of the symptoms. However, new steroid use and changes in method of use and dose were to be avoided during the trial. The patients were also instructed not to use any commercial eye drops they had on hand.

## 6. Studies and observation items

#### 1) Patient background

Together with questioning the patients as to ocular diseases that complicated the allergic conjunctivitis or vernal conjunctivitis, systemic diseases, allergic rhinitis, atopic dermatitis, past history of asthma, disease form (seasonal or nonseasonal), usual time of onset, age at first onset, severity, and treatment up to the present time, the participation of type I allergy was to be confirmed by verifying the cosinophil count in conjunctival scrapings, RAST IgE antibodies in the serum, positive antigens by intracutaneous reaction and scratch reaction (using five types of antigens: mites, house dust, orchard grass dust, Japanese cedar pollen, and ragweed pollen), and measuring the blood cosinophils and serum IgE value whenever possible.

The cosinophil count in the conjunctival scrapings and skin reactions were evaluated according to the positivity criteria of Table 2.

Test method	Positivity	· +++	++	+	
Eosinophil c conjunctival	ount in discharge or scraping	Clusters	Between (+++) and (++)	Weak response	0
Skin	Intracutaneous reaction	· Erythema ≥41 mm Wheals ≥15 mm	40-21 mm 14-10 mm	40-21 mm ≤9 mm	≤20 mm ≤9 mm
	Scratch reaction			Erythema ≥15 mm Wheals ≥5 mm	≤14 mm ' ≤4 mm

Table 2. Criteria for evaluation of the eceinophil count in eye dischargeor conjunctival scraping and the severity of skin reactions.

#### 2) Clinical symptoms

The following clinical symptoms were surveyed at the initial examination, at the beginning of the trial, 1, 2, 3, and 4 weeks after beginning the trial, and at the end of the trial. The severity was evaluated and recorded as severe (+++), moderate (++), mild (+), or none (-).

Ocular symptoms (subjective symptoms): pruritus, discharge, lacrimation, photophobia, feeling of a foreign object, eye pain.

Anterior segment findings (objective findings): congestion of the bulbar conjunctiva and chemosis, congestion, chemosis, follicles, and papillae of the palpebral conjunctiva, ulceration and erosion of the cornea, pathological changes in the ring.

The patients were also given eye allergy journals and instructed to record the severity of the ocular symptoms (subjective symptoms) each day to serve as a reference in evaluating the symptoms.

#### 3) Concomitant drugs

The name of the drug and dose (number of instillations, number of administrations and dose) were recorded when drugs other than HC ophthalmic solution were used.

# 4) Ophthalmological studies

The following studies were conducted whenever possible at the beginning and end of the trial: visual acuity, intraocular pressure, ophthalmoscopy, and slit lamp studies.

### 5) Clinical tests

The following tests were conducted whenever possible at the beginning and end of the trial.

Hematological studies: RBC, hemoglobin, hematocrit, WBC, leukocyte differential, platelet count.

Liver function tests: GOT, GPT, Al-P, bilirubin.

Kidney function tests: BUN, serum creatinine.

Urinalysis: glucose, protein, urobilinogen.

#### 6) Side effects

The symptoms, severity, date of appearance, and causal relationship with the trial drug were to be studied when side effects appeared and the treatment of the side effects and subsequent course to be recorded concretely.

#### 7. Clinical evaluation

#### 1) Improvement divided by symptom

The improvement divided by symptom of each item was evaluated as [1] marked improvement, [2] improvement, [3] some improvement, [4] no change, [5] exacerbation, or [6] no symptom by comparing the severity of the symptom during the preadministration observation period with the severity of the symptom after 2 weeks of administration and at the end of the trial.

#### 2) Global improvement

The global improvement was evaluated as [1] marked improvement, [2] improvement, [3] some improvement, [4] no change, [5] exacerbation, or [6] evaluation impossible by the attending physician by comparing the ocular symptoms and anterior segment findings at the end of the trial with those during the preadministration observation period.

#### 3) Overall safety

The overall safety was evaluated as [1] safe (absolutely no side effects or abnormal clinical test values), [2] fairly safe (mild side effects or abnormal clinical test values [no treatment required]), [3] safety doubtful (moderate side effects or abnormal clinical test values [instillation continued with some type of treatment]), [4] not safe (severe side effects or abnormal clinical test values [instillation discontinued]), or [5] evaluation impossible by the attending physician by comprehensive consideration of the existence of side effects and changes in clinical test values at the end of the trial.

#### 4) Utility

The utility was evaluated as [1] very useful, [2] useful, [3] fairly useful, [4] not particularly useful, [5] not useful, or [6] evaluation impossible by the attending physician by comprehensive consideration of the global improvement, overall safety, and patient background factors at the end of the trial.

#### **II. Trial Results**

#### 1. Patient background

Twenty-nine patients (0.05% solution: 14 subjects, 0.025% solution: 15 subjects) were administered HC ophthalmic solution during the trial. Table 3 shows the patient background. Table 4 shows a case summary. The majority of the 29 cases (26 cases, 90%) had allergic conjunctivitis. The disease form was nonseasonal and the severity was moderate in approximately half. The cosinophil count was at least (+) in the eye

discharge or conjunctival scrapings in 22 subjects (76%). Skin reactions and RAST were also positive in more than half.

Of the 29 subjects administered HC ophthalmic solution, one was excluded from the evaluation of efficacy for having other than the subject disease (phyletena) and two for inadequate washout of prior therapeutics (one administered 0.05% solution and one administered 0.025% solution). In cases that used steroid eye drops as prior treatment, one patient who switched the type of steroid eye drops at the beginning of instillation of the trial drug (0.05% solution) was used because steroid eye drops had been used before and after beginning instillation of the HC ophthalmic solution. Therefore, the efficacy was evaluated in 26 subjects (0.05% solution: 13 cases and 0.025% solution: 13 cases).

•		HC ophil	nalmic solution conce	entration .
	•	0.025%	0.05⊊ .	Total
Sex	make	8	3	11 (37.9%)
	female	7		18 (62.14)
Age ·	mean age (years)	36.8 (5-72)	22.4 (6-53)	29.8 (3-72)
Diagnosis	allergic conjunctivitis	13	13	26 (39.7%)
	vernal conjunctivitis	l l	1	2 (6.9%)
	other	1	0	1 (3.4%)
Disease form	seasonal	2	5	7 (24.1%)
	nonseasonal	9	5	14 (48.3%)
	unknown	4	. 4	8 (27.6%)
Seventy	severe	1 *	ı	2 (6.9%)
	moderate	8	10	18 (62.1%)
	mild -	.6	. 3	9 (31.0%)
Allergy background		·		
	+++	0 .	1	1 (3.4%)
Eosinophil count in eye	++	4	5. 4	9 (31.0%)
discharge or conjunctival	. +	8		12 (41,4%)
scraping		2	. 4	6 (20.7%) 1 (3.4%)
	unknown	1	. "	1 (3.470)
Skin reaction	positive	5	. 11	16 (55.2%)
(intracutaneous reaction	negative	2	0	2 (6.9%)
or scratch reaction)	บกผ่างพา	8	3	11 (37.9%)
	positive	6	11	17 (58.6%)
RAST	negative	8	3	11 (37.9%)
	นกโรกอพก	1	0	1 (3.4)

Table 3. Patient background.

9 5 2 5	Pukm, Sen, Age	Disgracels	Disease form	Severity	Conplication, atopic discase		Alkep background	frie frestnæret (derzeben)	Durathy of HC achterisher (W)	(Turantum Auth (Missien)
						1 in Itendenila	takagdila RAST, imperjanen raetter, wend renitu			
-	M.T. mule 9	Allergie crojuncifvils	Nonsessenal	PliM	fye: accumulative strain	<b>‡</b>	RAST: macs 1-1, rectand gracs 1-1 Japanese evelet (-1, represend 1-1, 110) (-)	74. Combon eye, abays, 1W  1) [74. Kinkense eye, abays, 4W	A) P	
3	O.H. female 46	Phylorena	Nonseasonal	PIIM		•	RAST: usins to tentual grass to I lipuases coder to coperat for 1111 to		MP	Kuskma A eye. daga, 1W
-	E.M. femsle 61:	Allergie conjunctivitis	Nonsessmal	Mith	Anque demodite	•	NAST the state of a testing from the state of the state o	01% Kinkma cyc dreps, 1W	Mt	
-	Id.Y. male 59	Allergie conjunctivitia	. Unknown	Mild	Eye: retinal veta Menasina secitation Systembel hyperensisa	. *			XI.	
~	N.T. femsle 62	Altergie conjunctivilis	Nonteatonal	Puly	Systemic hepatitis	. •	RAST mice (-), rectard grass (-), Japanese redar (-), repressal (-), III) (-)	Suberia cyc dago. I W	Alr.	
۰	O.S. femule 14	Albergle conjunctivitio	Sersonal	- Print	Albergke chimitia	<b>‡</b>	RAST: earland plan 1465. Japanew, with 1045. napwewyd 141. 1110 1449. Intowanen semelian: earland pras 1441. Japanew, weke 1441. napwewil 141. 1110 1419.		¥.	
٠	LS. Gemule 40	Alicrite	Seasonal	Moderate		•	RAST: judas tet, eestimal prass t. Lajumes sydne feet, rajumest feet, 1115 t.s. Kenneh neut- endamil prass tet. Lajumese tasku te 1. rajumest feet, 1113 t.s.		3,	
20	S.H. Auf 61	Alter gle conjunet britis	Unknown	Moderate	الامتاد بمهماناته مالامتاد تطعاناته		MAST; unbatet til ombud prove til bijunove eskir til ngasvel til 1111-11 hirominoven restlest: eteland prove til bijenove evela tek topsevel til 1111-11		, vv.	

Table 4-1. Summary of cases administered HC ophthalmic solution (1).

Cese No.			Ocular .	Ocular symptoms		·	Duffer		Palyched	·	- the	Heraff crafuativa	·	Nike etkeets and absammal etinical test values	County
	Prantitus	Discharge	Lecrimetion	Photophobia	Peeling of foreign object	Eye pain	Congestion	Cherinais	Crapestua	Chemenia	(ibdol inporters	t hvrall sakty	thillty		
-	Improvement						Inprovensed		ingervence		ingwarmen	Nate	מאלווון		Kinderon eye washo
~					improvement		Improvenent				inymavnava	Z.	sem:what useful	Musi	Excluded from of efficiency for the date authors.
-	some Improvement				sone improvement Improvement	Improvement			caaveholim	csavrhalbu	. cravybainm	uk.	ne parkulady nadul	Aprel	Hackahad foun- of officially for o of paler thron
-	Inprovenen				Improvement		some improve- ment		eraccitation	·	eune ingenverau	şış	iniwalist Injun	MIIM	
~	no change	og change					·				ine champe	in fo	sourcelus exelui	я Э.	
•	Іпрочетен	tome Improvenent			some Improvement	_	no change	sone	un change	no change	num. Indament	Ė	na-tuf	2	
-	Improve- nread	pome Improvement	no change	no change	no change		some improve- ment	nı change	neme insperve-	ne change	uque, unque inque	Ì	us pankalariy mefut	ž	
•	no change		same Improve- men			exacerbation	no change	no change	on clampe	odumbo en	w.dank.	· .	e e un ful	Buck	·
							•							٠	

0.025%

Cinna				¢			•	
Paraiwa of Itt gahrimiatraiwa (W)		MF	, ws	MF	Mř	Mr .	Wa	Mr ·
('the irrailmen (chezikeit		·						
Alkty kadyneni	RAST, intravilations residen, seath	RANT: mines 14441, endund prave t. Japanese coder (-1. rapavent -1. 11) 1441	RANT; miss extended practed. Japanese color extrapassod extilities Nerolethese extended practed Aquasse color extrapassod extilities	RASSE miss to recland grow to. Japanese cooker to reproved to 1110 to Second host miss to k technic prior to kipanese cooker to reproved to 1110 to feel in the cooker to	RAST: index (+++) included pravet.). Japanese coder (+, represed (+, III) (+++)	RAST; mins (1404), uncland pravo (-). Japanese coche (-), inpurval (-), 1119 (4)	HANT; some extendent gravet: Jegones extentex representes III ex Intractionente sencion extende grave (-), Japonese exclarate extendentes (-),	RAST; nuts 1-1, exchad prave 1. Japanese codu 1-1, rapavosd 1-1, lill 1-1 Immanianeses mendes enits 1-1, eschant prass 1-1, faponese vodu 1-1, rapavod 1-1
	Essin equits	.‡	•	•			• .	•
Cremplications, stopic disease					Alopic dematitis		Aleryk etiniis	Altergie rhinhis
Severily.	:	Moderat	жодели	Modern '	Severe	Modera	Moderal	Moderal
Disease		Nonserson	Unknown	Nonscion	Nonseatona 1	Nonsessons	Nonscasona J	Unknows
Oispnesis		Allergie conjunctivitis	Alkrgk conjunctivitis	Alferjić cosjuscivits	Allergic conjunctivitis	Alteryte conjunctivitis	Affeetje coejunciiviiis	Vertal conjunctivitis
Patlend, Sea,		H.M. female 61	K.M. male 71	K.K. female 73	M.T. msk 9	H.S. mak	Y.Y. mule 5	a.H. auk
ðź		6	ē	=	c	2	2	n

Table 4-1. Summary of cases administered HC ophthalmir enterior 12

IIC Concuevion								·
Daration of HC administration (W)		At .	<b>≩</b>	*	///	Alt	MF	м
Price (resulted)								
Alkypy background	KANT, infrantaments teaching, extrict reaction	RAST; pun 1000, notal gras 1.1 faunze grâst (1, regenel f. 1. 1111, 1000)	RASE nike (++), ordeni grav (+, fajumas voda (++), fajumasid (-), [[]) (++)	RANT miss (+, included gras) (+, liquinge redar) ( regened (+, 111) (+) (incrementer) (reserve) (incrementer) (reserve) (incrementer) (regened (+, 111) (+)	RAST: mix-1++1, recland pray (+++1, Japanese exclar (+++), represented (+-1) (+++) (mixeranese excellente excland pass (++1, Japanese exclar (++), represented (++), [1]) (++)	RANT, mine (et. regizat pras tel. Japanese exha te L ragenced (e. 1. 117) e.) Introdumens reachier; eschari prass tel. Japanese serlar tel, regeneed to et. 110 to e.)	RAST: mine to technel gravi to Dijumese ooksi to Linguased to Hill to Infrastansian mesticat, nechnil gravi to Jajumese koske to inguased to Lill to	RANT: mitor 1646 t sectual prov. 1641 t. Injumor. schaftest reprint 1646 t. 1131103 immonianous montiss" sectual prov. 14 Injunor. sodar 1641, represent 1644 t. 113143
	Bosingtile	÷		•	<b>‡</b>			
Disposals [sk:]		Aupie demonits			Oyer myryda Systemier stopie dermaitits		Alkryk miniis	
Severity	•	Модети	Moderate	Moderate .	Moderate	Moderate	РІМ	Москти
Disease form		Nonseasonal	Nonsensonal	Nonsessons	Unknown	Seasonal	Scatona)	Nonsessons
Diagnosis		Allergle conjunctivitis	Allergic conjunctivitis	Allergie conjunctivitis	Allergie conjunctivitis	Altergie conjunctivitis	Altertie conjunctività	Altergic conjunctivitis
Pullers, Sez, Age		O.R. make	LY. female 53	S.S. female 52	H.K. female 12	S.M. Kmule 13	O.M. female 32	N.M. female 39
94		•		n :	•	~	•	

Table 4-2. Summary of cases administered HC ophthalmic solution (1).

C3

0.05%

7

mr.L

÷

To the

næ.(nj

Ţ

thiling

(Norall salety ž.

n~-ful

Š

uncful

. rafe.

Ę

n Krijin

K.

į

uxeful

4

ib an

uw-fu]

ž

Sak ciffects and abaremal clinical kw cuban

A	Pruftus Improvement Improvement murked improvement	Dicharps	Ocults  Lacrimation  no charge  ingrovement  some ingrove- ment	Oculu symptoms  Use marked improvement ingrovement ing	Feeling of fareign  Cyce pain  Improvement  marked improvement  ment  improvement  ment  improvement  ment	Cengealian ingenvernent ingenvernert ingenve	Chemenis inquarement inquarement inquarement inquarement			Cibakai hayanvenarai ingenvenarai ingenvenarai ingenvenarai ingenvenarai ingenerai ing	<del> </del>
	marked Improvement	Improvenent		Improvement	eo change.	some inprovency insuked inverse	nerked layeure- nem	ingermenters	arated sayman	myanvinta myanvinta	
1											

0.05%

1	Ś	Q
ì	ì	
•	Ċ	j
e		ś
•	٦	

A 전	Pulent, Sar, Age	Olagausis	Disess form	Severity	Canplications, atopic disease		Alkepy backpround	(Price Dystinate)	Durahen of HC attornistration (W)	Communicate shups (duration)
						Ensinophils	RAST, intraviences reaches, actuch icurhan			
eq	M.S. femble 11	Verial conjunctivitis	Sessons	Severe	Alerpic raintity, stupic dermatitis, asthma	‡	RAST: nites (++), usthard grass (-1, Japunese verbs (++), HI) (+++)	ft.1's 1 Teamwijachen, 1 W Tribracin, 1 W	A.	Salperiu eye dogo, 4W Minkros A sdemena 0.14 Kindros eye shega, 4W
• .	12A. Gemale 12	Alkryle conjunctivits	<b>О</b> лчасти	Moderate		•	RAST: nibra t-t. rectual prass (+++t. Japana; kwar t-k. rajeword t-t. Hit t-t) Infransiabous reacting: declard prass t-t. Japana; extar (-t. rajeword t-k. Hit) (+t.		A	
ō.	N.T. female 3.S	Allergie conjunctivitis	Senonal	МГЫ	Allergic relatifs,	<b>‡</b>	RACT: mics (++), unfurd grass (++++), Japanose verbar (++), rayweed (+), HI) (++), infrance verbar (++), Hi) (++), infrance verbar (++), Hi) (+), vigured (++), Hi) (+)	·	3.	
11	9। १९ १९	Albergie conjunctivitis	Unknowns	Moderate	Systemic: myocardills	•	RANT: rates (+++), restand prin (+), Japanas, celar (-), rapweed (+), HD (+++) Istantaneous rescition; vechand priss (-), Japaneous retar (+), rapweed (-), HD (++)	DD239-18"-qendahmic mduhen, W	¥.	
<b>11</b> .	O.T. female	Allergie conjunctiviti	Seasonal	Moderate	Alfergle minids	:	RAST: subset (++++) archard grass (+), Injunyer, verdet (-), reguered (+), HD (++), intracherus rezelent; erchard grass (+), Jajuaner, verdet (-), raguered (+), HD (++)		Ą	
2	Y.T. female 14	Ailerzle conjunctivitis	Nottersnari	PIIM	Angele demantiis	*	RAST: mine (+++ Lill) (+)  reduction continues and principul (+) Indianal states  reduction continues and (+)  reduction continues (+)		Air	
<u>*</u>	O.M.	Alleryle confractivits	. Unknown	Moderate		:	RAST: minst tooool, vorbant grauter, Japaneer setter toook ngseerede, Hillioop letter too reaches; sectant grass es. Japaneer setter (s. represed e. 1. Hillio)		νν:	

18to 4.2. Summery of cases administered IIC ophibalmic solution (2).

ě.

. switsl

<u>;</u>

E M

3

j

SAME.

ux-fal

ż

firchales from evaluation of efferty for no washing in join the parties.

ă.

E TE

÷

mar.

wry owled

all.

is its.

urctil

ž

aranomakui

ingworms

nane inperne-

SHIP

some inquiremens

> some Improvement

Stends vanched at the Explanate of HC maillainer

4

tairly awful

ž,

main, tilyanav

Aunt. impermentated

same Inprove-

no change

sume improve-

Improvement

Lectimation

Discharge

President

Italiay

Swend takey

Citated

( Terrenda

Compension

Christinh

Congestina

Eye paln

Feeling of foreign object

( innibation

Site effects and abunerital elitical test value

(Norall evuluation)

I'shydral

9cht

Oculer symptoms

S S

											Larred on Immunity	
2	10 Improvences	some Improvement	some improve-		Improventent		some improve-	Ingrincence	nent indoors.	inportered	IINAH	- 1
											the art of the same	
=	some Improvement		sone improve- ment				no change	का राजकृत	And Charles			
								1	inner inner	Ama	m.vil.vunknj	
2	amos		so change , some improve-				sone improve-	ingerveteet	uncup .	Ē		
								1	1	as channe	in-an-coupen	
=	tome					some Improvement	sone improve-	Improventent				
	Improvement								no change	en chaise	phanenani	
=	some	no change			some improvement			inpowental				
	Ingrovensia									4		
		,		440 711 Canh		ŧ						

0.05%

Table 4-2. Summary of cases administered HC opi

19-0041

2. Global improvement

Table 5 shows the gobal improvement by the two solutions. While the percentage evaluated as at least improved was 85% by 0.05% solution, it was 23% by 0.025% solution, giving the 0.05% solution a significantly higher improvement rate (p < 0.01, U-test and x2-test).

Drug	Nathed		Shybi		Esserbativa	Treat	At least improved	Te	ed.
concentration	inprovement	Impenveniens	îniproventent	No change	ECATIONE	,,,,,,		U-cc pi	४.न€ष
0.025%	a ·	3	<b>b</b> .	4	0	13	231	p<001	p<001
0.05%	. 3	5	2	n	0	13	311.6	•	<u></u> _

Table 5. Clobal improvement.

3. Improvement divided by symptoms

An examination of the improvement of the subjective symptoms at the end of the trial (Table 6) showed high improvement rates in both eyes for pruritus, photophobia, and feeling of a foreign object which are characteristic subjective symptoms in allergic conjunctivitis. However, the improvement rates were 8 to 13% higher by 0.05% solution than 0.025% solution. While the improvement rate of eye pain was 75% by 0.05% solution, that by 0.025% solution was low at 33%. An examination of the improvement of the objective fundings (Table 7) shows an improvement rate (at least improvement) of bulbar conjunctival congestion of 46% by 0.05% solution (at least some improvement: 100%, the same below) in contrast to 25% (42%) by 0.025% solution. The improvement rate by 0.05% solution was thus significantly higher (p < 0.05, U-test). The improvement rate of bulbar chemosis as well was 46% (85%) by 0.05% solution as opposed to 29% (43%) by 0.025% solution. In palpebral conjunctiva congestion and chemosis as well, 0.05% solution gave significantly higher improvement rates than 0.025% solution. Neither solution produced marked improvement of palpebral conjunctiva follicles, papillae, or changes in the ring.

. Symptoms	Drug concentration (%)	Improvement divided by symptom								Test	
		Marked Improvement	Improvement	Some improvement	No change	Exacerbation	Total	At least Improved (%)	U-test	g'-test (at least improved)	
Pruritus	0.025 0.05	1 2	4 3	;	2 1 ·	0	10 12	20.0 0.05	24	. NS	
Discourge	0.025 0.05	i	1 2	1	2 2	0	7 5	28.6 40.0	NS	М2	
Lacrimation	0.025 0.05	i o	1 2	2 3	?	0	. 6	28.6 33.3	NS	NS	
Photophobia	0.025 0.05	;	2 4	°,	100	8	8	75.0	NS	NS.	
Feeling of foreign object	0.023 0.03	. 0	3	1	2	0	:	62.5 75.0	NS	NS	
Eye pain	0.025 0.05	0	2 .	1	3	2 0	6	33.3 75.0	NS	NS	

Table 6. Improvement of subjective symptoms by HC ophthalmic solution.

Symptoms	on (%)		Tot							
	GH ( 4 )	Marked improveme at	Improveme rst	Some improveme nt	No chan ge	Era <del>cab</del> ai .	ਿਰ ਸ਼ੀ	At least improved (%) (2) least some improvement	U-test	gi-tess tat leas improv di
ulbar conjuncti	<u>.</u>	<u> </u>	l					•		
Conges tion	0.025 0.05	1 0	2 6	;	7 0	. 0	22	25 0 (4).6) 46.2 (100)	p < 0.05	. NS
Chemo sis	0.025 0.03	.1	1 5	1,	;	0	7	28 6 (42.9) 46.2 (84.6)	NS	NS
alpebral conjus	ktiva	<u> </u>	<u></u>	<u>l</u>	J—	1	.l.,			
Conges	0.025	0 3	1 3	;	7 2	1 0	12 12	16.7 (33.3) 50 0 (\$3.3)	p < 0.03	NS
Chemo sis	0.025 0.03	0 2	. ;	0	6 2		. 13	(4,3 (14,3) 53.8 (84.6)	p <b>&lt;</b> 0.01	NS
. Fallicle	0.025	. 0	. 0	3 6	6 5	0	1.11	.0 (45.5) 0 (54.5)	NS	NS
Papillac	0.025 0.03	0 0	. 8	2 3	1	0	3	0 (66.7) 0 (60.0)	NS	N:
Cornea	.1	<del></del>	<u></u>			<u>.l</u>	<del> ا</del> ب			
Ulceradi 00	0.025 0.05	0	0	Ŷ	0	0	°	0 (100)		
Erosion	0.025 0.05	8	. 8	0	0 2	8	0 2	0 (0)	•	
Ring	0.025	1 ;	1 1	1	1;	0	5 5	20.0 (20.0)	NS	N

Table 7. Improvement of objective findings by HC ophthalmic solution.

# 4. Overall safety None of the 29 subjects (0.05% solution: 14 cases and 0.025% solution: 15 cases) administered HC ophthalmic solution presented any side effects or abnormal clinical test values during the trial. The overall safety that considered the side effects and abnormal clinical test values was judged to be "safe" in all cases.

5. Utility
Table 8 shows the evaluation of utility by the attending physician by considering the global improvement, overall safety, and patient background factors. While 0.05% solution was found to be at least useful in 12 subjects (92%), 0.025% solution was only at least useful in four (31%). There was thus a significant difference between the 0.05% and 0.025% solutions (p < 0.01, U-test and χ2-test).</p>

Drug concentration (%)	Very useful	Useful	Somewhat useful	Not particularly useful	Not useful	Total	At least useful (#)	Test .	
				52.101	0.X.141			U-test	χ²-test
0.025 0.05	0	4	S 1	2 0	2 0	13 13	30.8 92.3	p < 0.01	p<0.01

Table 8. Utility.

# III. Discussion

Ketotifen ophthalmic solution (HC ophthalmic solution) is reported to dose-dependently suppress conjunctivitis in experimental allergic conjunctivitis models [9]. It is of great interest whether or not the dose dependence evidenced in animal experiments is reflected in clinical application. The efficacy and safety were compared here by administering 0.05% and 0.025% HC ophthalmic solutions four times a day for 4 weeks to patients with allergic conjunctivitis and vernal conjunctivitis in which the participation of type I allergy had been confirmed.

While the efficacy expressed by the global improvement rate showed an efficacy rate (at least improved) of 85% by 0.05% solution, the rate was only 23% by 0.025% solution. 0.05% solution was thus significantly superior. An investigation as the improvement of the subjective symptoms found both solutions to give high efficacy rates in pruritus, photophobia, and feeling of a foreign object. However, 0.05% solution gave 8 to 13% higher improvement rates than 0.025% solution. An examination of the improvement of the objective symptoms found the improvement rate in conjunctival congestion to be 46% (bulbar) and 50% (palpebral) by 0.05% solution in contrast to 25% (bulbar) and 17% (palpebral) by 0.025% solution. 0.05% solution thus gave significantly higher improvement rates. The rates of improvement of chemosis as well were higher by 0.05% solution with 46% (bulbar) and 54% (palpebral) by 0.05% solution in comparison to 29% (bulbar) and 14% (palpebral) by 0.025% solution. It is assumed that in the final analysis the differences in the improvement rates of bulbar and palpebral conjunctiva congestion and chemosis by 0.05% and 0.025% solution produced the difference in the evaluation of global improvement. On the other hand, improvement of palpebral conjunctival follicles, papillae, and pathological changes in the ring was very low by both solutions. Similar results are reported for another antiallergy drug, disodium cromoglycate [10]. A satisfactory therapeutic effect is probably not obtained in follicles, papillae, and changes in the ring with short term trials of only 4 weeks.

As for the safety, there were no side effects or abnormal clinical test values at all during the trial. HC ophthalmic solution can be called a relatively safe ophthalmic solution because the overall safety was judged to be good in all cases.

To summarize the above, a comparison of the efficacy and safety of 0.05% HC ophthalmic solution and 0.025% HC ophthalmic solution showed 0.05% solution to be better than 0.025% solution in terms of efficacy. As for safety, no side effects or abnormal clinical test values were found in either group. Although it is difficult to draw a conclusion from the present results because only 30 cases were studied here in the two groups combined, the results generally appear to indicate that 0.05% HC ophthalmic solution is superior to 0.025% HC ophthalmic solution.

# Summary

- (1) The efficacy and safety were compared by using ketotifen ophthalmic solutions (0.05% and 0.025% solutions) in 29 patients with allergic conjunctivitis and vernal conjunctivitis.
- (2) In the global improvement, 85% of those administered 0.05% solution were evaluated as at least improved in comparison to 23% by 0.025% solution. 0.05% solution thus gave a significantly higher improvement rate.
- (3) There were no side effects or abnormal clinical test values at all in either group during the trial.
- (4) The evaluation of utility based comprehensively on efficacy and safety was significantly higher by 0.05% solution than 0.025% solution. 0.05% solution is therefore believed to be superior to 0.025% solution.

#### References

- [1] Martin U., et al: The pharmacological properties of a new orally active antianaphlactic compound: Ketotifen, a benzocycloheptathiophene. Arneim. Forsch., 28:770-782, 1987.
- [2] Akaboshi, Y. et al.: Effect of HC20-511 (ketotifen) on histamine release from rat skin by the histamine liberator compound 48/80. Arerugi no Rinsho, 5:401-404, 1985.
- [3] Neu, U. M., et al: Pharmacology of Ketotifen. Res. Clin. Forms, 4:9-16, 1982.
- [4] Kumatani, A. et al.: Pharmacological study of a new oral bronchial asthma preventative. Medical Sandoz, 8:87-93, 1980.
- [5] Aoki, H. et al.: Effect of HC20-511 on isolated guinea pig tracheal smooth muscle. Yakuri to Chiryo, 7:1571-1577, 1979.
- [6] Kawasaki, H. et al.: Eye irritancy test of ketotifen fumarate ophthalmic solution in rabbits (II). Eye irritancy by 4-week and 13-week instillation. Iyakuhin Kenkyu, 19(5):827-838, 1988.
- [7] Nakayasu, K. et al.: Safety test of ketotifen ophthalmic solution for the outer and anterior regions. Rinsho Iyaku, 4(12):2357-2369, 1988.
- [8] Mikuni, I. et al.: Study of the efficacy and safety of ketotifen ophthalmic solution in allergic conjunctivitis and vernal conjunctivitis Results of a multiclinic open trial. Rinsho Iyaku, 4(12):2371-2383, 1988.
- [9] Yamaguchi, T. et al.: Effects of ketotifen fumarate ophthalmic solution on experimental conjunctivitis in rats and guines pigs. Iyakuhin Kenkyu, 20(1):48-56, 1989.
- [10] Uchida, Y. et al.: Therapeutic results of disodium cromoglycate (Intal) ophthalmic solution in vernal conjunctivitis and allergic conjunctivitis. Ganka Rinsho Iho, 75(6):725-746, 1981.